HIGHLIGHTS
- who: Ke Wang from the Department Medical University, Xi`an, China have published the Article: Metabolic interaction: tumor-derived lactate inhibiting CD8+ T cell cytotoxicity in a novel route, in the Journal: (JOURNAL) of 26/08/2022
SUMMARY
As a FDA approved drug for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular IDH1 mutated cholangiocarcinoma in 2021, AG-120 (Ivosidenib, Tibsovo) conferred them with a median follow-up of 6.9 months and median overall survival (OS) of 10.3 months, compared with that of 7.5 months in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.